TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33992268

Group type: EXPERIMENTAL
Intervention: 50% dextrose phonophoresis for 5 min and therapeutic ultrasound for 5 min
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) with frequency of 50 HZ for 50 min
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional physiotherapy ultrasound for 5 min
Number of subjects: 45
Study: 32397966

Group type: EXPERIMENTAL
Intervention: Specialist LINK
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: PCN Clinical Pathways
Number of subjects: 251
Study: 35369705

Group type: EXPERIMENTAL
Intervention: Vupanorsen (60 mg every 2 weeks)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Vupanorsen (80 mg every 2 weeks)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Vupanorsen (various doses)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 34218802

Group type: EXPERIMENTAL
Intervention: Doxycycline-based quadruple regimen (bismuth subsalicylate 524 mg four times daily, doxycycline 100 mg, tinidazole 500 mg, and esomeprazole 20 mg, each twice per day for 2 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Levofloxacin concomitant regimen (levofloxacin 500 mg daily, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg each twice per day for two weeks)
Number of subjects: 78
Study: 34602338

Group type: EXPERIMENTAL
Intervention: Maternal voice intervention (voice recordings of the mother reading a children's book played during heel stick procedure once daily for 3 consecutive days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no maternal voice intervention)
Number of subjects: 64
Study: 34320709

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACTx)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Surgical treatment only (Control)
Number of subjects: 45
Study: 37744073

Group type: EXPERIMENTAL
Intervention: Usual care plus remotely delivered EMDR R-TEP
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care alone (controls)
Number of subjects: 26
Study: 34236672

Group type: EXPERIMENTAL
Intervention: Peanut allergen powder‐dnfp (PTAH) oral immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35459665

Group type: EXPERIMENTAL
Intervention: Home energy intervention (Victorian Healthy Homes Program)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no intervention before winter)
Number of subjects: 1000
Study: 32723193

Group type: EXPERIMENTAL
Intervention: 350 mg dose of herbal supplement (70:30 blend of Rhaponticum carthamoides extract and Rhodiola rosea extract)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 175 mg dose of herbal supplement plus 175 mg of maltodextrin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All interventions (herbal supplement and placebo)
Number of subjects: 30
Study: 36129733

Group type: EXPERIMENTAL
Intervention: Endocare (virtual reality digital treatment)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 2D digital control
Number of subjects: 45
Study: 33821898

Group type: EXPERIMENTAL
Intervention: Low-intensity walking exercise (n=116)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: High-intensity walking exercise (n=124)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Nonexercise control (n=65)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Between-group comparison (low-intensity vs high-intensity)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Between-group comparison (low-intensity vs nonexercise control)
Number of subjects: 305
Study: 35810744

Group type: EXPERIMENTAL
Intervention: Bronchoscopic instillation of voriconazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medical therapy (MT) alone
Number of subjects: 60
Study: 33538091

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (target <120 mm Hg)
Number of subjects: 9210

Group type: COMPARATOR
Intervention: Standard systolic blood pressure control (target <140 mm Hg)
Number of subjects: 9210

Group type: EXPERIMENTAL
Intervention: Each 5 kg/m2 increase in baseline BMI
Number of subjects: 9210
Study: 34623507

Group type: EXPERIMENTAL
Intervention: Local application of hyaluronic acid (HA) on both donor and recipient sites
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline application (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local application of hyaluronic acid (HA)
Number of subjects: 24
Study: 34339370

Group type: EXPERIMENTAL
Intervention: STRAP (Style Transfer Augmentation)
Number of subjects: 0
Study: 36456021

Group type: EXPERIMENTAL
Intervention: Inulin (20 g/day of powdered supplement dissolved in water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maltodextrin (placebo control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 0
Study: 32316168

Group type: EXPERIMENTAL
Intervention: Altitude training camp for 11 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no altitude training)
Number of subjects: 20
Study: 34807243

Group type: EXPERIMENTAL
Intervention: Aducanumab (10 mg/kg)
Number of subjects: 3285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3285
Study: 35352383

Group type: EXPERIMENTAL
Intervention: Swallowing training combined with nutritional intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine health counseling and swallowing training
Number of subjects: 66
Study: 33307932

Group type: EXPERIMENTAL
Intervention: Adapted consent form using Fuzzy Trace Theory
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard consent form
Number of subjects: 86
Study: 34743011

Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) for identifying uncontrolled symptoms
Number of subjects: 296
Study: 33054727

Group type: EXPERIMENTAL
Intervention: Early ultrafiltration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Torasemide plus tolvaptan
Number of subjects: 100
Study: 33548747

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham Therapeutic Touch (STT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 96
Study: 35123566

Group type: EXPERIMENTAL
Intervention: Culturally adapted brief negotiational intervention (PPKAY) with standard SMS booster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally adapted brief negotiational intervention (PPKAY) with personalized SMS booster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally adapted brief negotiational intervention (PPKAY) without SMS booster
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPKAY with standard SMS booster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPKAY with personalized SMS booster
Number of subjects: 0
Study: 32796410

Group type: EXPERIMENTAL
Intervention: Kyphosis exercise and posture training intervention (twice weekly for 3 months)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Kyphosis exercise and posture training intervention
Number of subjects: 103
Study: 35447622

Group type: EXPERIMENTAL
Intervention: Thrice-weekly moderate-intensity aerobic-based exercise over 24 weeks (including 8 weeks of supervised in-center and home-based sessions followed by 16 weeks of home-based sessions)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Thrice-weekly moderate-intensity aerobic-based exercise
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study: 34555409

Group type: EXPERIMENTAL
Intervention: MAST (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: MAST-placebo (n = 22)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (MAST and MAST-placebo)
Number of subjects: 45
Study: 35339397

Group type: EXPERIMENTAL
Intervention: Homeopathic medicine Natrum muriaticum LM2
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 34217657

Group type: EXPERIMENTAL
Intervention: Right Ventricular (RV) pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 30
Study: 32705417

Group type: EXPERIMENTAL
Intervention: Rocuronium 1 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 40
Study: 36045877

Group type: EXPERIMENTAL
Intervention: IM progesterone in oil (25 mg daily)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: IM progesterone in oil (50 mg daily)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Progesterone suppository (400 mg daily)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Progesterone suppository (800 mg daily; 400 mg twice daily)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone suppository groups
Number of subjects: 312

Group type: COMPARATOR
Intervention: IM progesterone groups
Number of subjects: 312
Study: 32173113

Group type: EXPERIMENTAL
Intervention: Suprachoroidally injected CLS‐TA
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 160
Study: 34664221

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (VD3) 4000 IU daily for 3 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 32770661

Group type: EXPERIMENTAL
Intervention: 75 grams of oral glucose + 6 grams of oral sodium chloride (NaCl) load
Number of subjects: 10

Group type: COMPARATOR
Intervention: 75 grams of glucose alone
Number of subjects: 10
Study: 35916700

Group type: EXPERIMENTAL
Intervention: Full imi intervention web application (treatment)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Resource page-only version of the imi site (control)
Number of subjects: 270
Study: 33772806

Group type: EXPERIMENTAL
Intervention: Approach-positive faces (n = 12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Balanced approach of positive and neutral faces (n = 13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both conditions (AAT + BA)
Number of subjects: 25
Study: 32731424

Group type: COMPARATOR
Intervention: Only diet suggestions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both diet and exercise prescription
Number of subjects: 100
Study: 35485687

Group type: EXPERIMENTAL
Intervention: Oral tablets of zinc sulfate twice a day for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no placebo)
Number of subjects: 80
Study: 34194139

Group type: EXPERIMENTAL
Intervention: Tension adjustment technique under saddle anesthesia (Group II)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tension-free technique (Group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 35689014

Group type: EXPERIMENTAL
Intervention: Messages optimized for central route processing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Messages optimized for peripheral route processing
Number of subjects: 50
Study: 32902928

Group type: EXPERIMENTAL
Intervention: Gluten ingestion during low FODMAP diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Habitual gluten-free diet
Number of subjects: 33
Study: 32331091

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (56-84 mg twice-weekly for 4 weeks) + oral antidepressant (AD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (56-84 mg once-weekly or once-every-other-week) + oral antidepressant (AD)
Number of subjects: 0
Study: 34762850

Group type: EXPERIMENTAL
Intervention: IANB
Number of subjects: 96

Group type: COMPARATOR
Intervention: INF
Number of subjects: 96
Study: 34319487

Group type: EXPERIMENTAL
Intervention: Pocket-sized ultrasound devices (PUDs)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard ultrasound devices (SUDs)
Number of subjects: 52
Study: 35040102

Group type: EXPERIMENTAL
Intervention: Treatment guided by serial ultrasound of the inferior vena cava‐collapsibility index (IVC‐CI) and B‐lines on lung ultrasound (LUS)
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 2040
Study: 33165621

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 479
Study: 35916128

Group type: EXPERIMENTAL
Intervention: Lisinopril (up to 40 mg)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Candesartan (up to 32 mg)
Number of subjects: 141
Study: 32646930

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33640347

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 406
Study: 32887594

Group type: EXPERIMENTAL
Intervention: New model of care for knee osteoarthritis (12-week community based, individualized, multidisciplinary approach)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 20
Study: 35522197

Group type: EXPERIMENTAL
Intervention: Low-temperature plasma (LTP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 33502448

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for surgical predictions
Number of subjects: 683
Study: 35918101

Group type: EXPERIMENTAL
Intervention: Positivity-oriented photography intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study: 33476542

Group type: EXPERIMENTAL
Intervention: High-calorie group (calorie-enriched formula)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional group (standard formula)
Number of subjects: 100
Study: 32083298

Group type: EXPERIMENTAL
Intervention: Nanocarbon group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32180248

Group type: EXPERIMENTAL
Intervention: SPOT GRADE intervention (surgical bleeding severity scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized sequence of controlled bleeding videos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kappa statistic methodology
Number of subjects: 0
Study: 35042738

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 26 weeks
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Increased stroke severity (measured by NIHSS)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Past depression
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Being married or partnered
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Cultural context (Australia and New Zealand vs Vietnam)
Number of subjects: 1221
Study: 33798090

Group type: EXPERIMENTAL
Intervention: Medication-related harm identified through retrospective review of patient records.
Number of subjects: 9076
Study: 32643358

Group type: EXPERIMENTAL
Intervention: QLB dexmedetomidine interfascial (QD IF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: QLB dexmedetomidine intravenous (QD IV)
Number of subjects: 50
Study: 35758127

Group type: EXPERIMENTAL
Intervention: FOLFOX plus cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX alone
Number of subjects: 0
Study: 34461255

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 84
Study: 32228330

Group type: EXPERIMENTAL
Intervention: 5-mg fast-release melatonin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 32708428

Group type: EXPERIMENTAL
Intervention: Hydrolysed high-protein, lactose-free milkshakes (500 mL, 50 g protein)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ordinary high-protein, lactose-free milkshakes (500 mL, 50 g protein)
Number of subjects: 41
Study: 35996073

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.04 mg/kg) and atropine (0.02 mg/kg) intravenously
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 34590717

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 32838813

Group type: EXPERIMENTAL
Intervention: Multiple doses of oral ondansetron following ED visit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of oral ondansetron
Number of subjects: 0
Study: 35029357

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study: 33710724

Group type: EXPERIMENTAL
Intervention: PECS II block with 30 mL 0.25% bupivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: RIB with 30 mL 0.25% bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 90
Study: 32917171

Group type: EXPERIMENTAL
Intervention: Internet use among the elderly
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Favorite online activity
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Health information obtained through the Internet
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Demand for smart services
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Factors influencing Internet use
Number of subjects: 669
Study: 616795279

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 0.5 mg/kg/tpd with beta-lactam plus macrolide
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo with beta-lactam plus macrolide
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo with beta-lactam plus fluoroquinolone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Methylprednisolone with beta-lactam plus fluoroquinolone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall treatment failure
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 106
Study: 35251297

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional open surgery
Number of subjects: 80
Study: 33961943

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 300 mg once daily for 6 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 125
Study: 32331069

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 464
Study: 33531062

Group type: EXPERIMENTAL
Intervention: Membrane sweep
Number of subjects: 0

Group type: COMPARATOR
Intervention: No membrane sweep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early sweep (from 39 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late sweep (from 40 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single sweep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly sweep
Number of subjects: 0
Study: 36078243

Group type: EXPERIMENTAL
Intervention: 2 consecutive night shifts
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 4 consecutive night shifts
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 7 consecutive night shifts
Number of subjects: 73

Group type: COMPARATOR
Intervention: Recovery days
Number of subjects: 73
Study: 34033621

Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg·kg‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 33739424

Group type: EXPERIMENTAL
Intervention: Self-compassion messaging
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Traditional messaging
Number of subjects: 655

Group type: COMPARATOR
Intervention: Image-only control
Number of subjects: 655
Study: 33077866

Group type: EXPERIMENTAL
Intervention: CAR-T cells
Number of subjects: 43
Study: 32114063

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling (UGN) combined with corticosteroid injection
Number of subjects: 82

Group type: COMPARATOR
Intervention: High-energy extracorporeal shock wave therapy (ESWT)
Number of subjects: 82
Study: 34394778

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 32022662

Group type: EXPERIMENTAL
Intervention: Traffic noise exposure
Number of subjects: 12963

Group type: EXPERIMENTAL
Intervention: Proximity to traffic without disturbing noise
Number of subjects: 12963
Study: 34081073

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (4200 mg)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study: 33550815

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 34265569

Group type: EXPERIMENTAL
Intervention: Vitamin E + C supplementation
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 32937620

Group type: EXPERIMENTAL
Intervention: Seated posture during a simulated workday of prolonged sitting for 7.5 hours
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Supine posture during a simulated workday of prolonged sitting for 7.5 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: Seated posture versus supine posture
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Seated posture
Number of subjects: 25
Study: 35897052

Group type: EXPERIMENTAL
Intervention: Maintenance of biologic disease-modifying antirheumatic drugs (bDMARDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gradual reduction of bDMARD dosage by 50% every 3 months up to complete stop
Number of subjects: 0
Study: 34387411

Group type: EXPERIMENTAL
Intervention: IDegLira (max. dose 50 U degludec/1.8 mg liraglutide)
Number of subjects: 453

Group type: COMPARATOR
Intervention: degludec (max. 50 U/day)
Number of subjects: 453